Breaking Finance News

Dynavax Technologies Corporation (NASDAQ:DVAX) has been upgraded to Hold in a report by Zacks Investment Research today.

Zacks Investment Research has upgraded Dynavax Technologies Corporation (NASDAQ:DVAX) to Hold in a report released on 9/29/2016.

Only yesterday Dynavax Technologies Corporation (NASDAQ:DVAX) traded -7.27% lower at $10.33. Dynavax Technologies Corporation’s 50-day moving average is $13.76 and its 200-day moving average is $15.96. The last stock close price is down -35.26% relative to the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the same time period. 1,683,994 shares of the stock were exchanged, up from an avg. volume of 1,237,000

Performance Chart

Dynavax Technologies Corporation (NASDAQ:DVAX)

With a total market value of $0, Dynavax Technologies Corporation has 52 week low of $10.14 and a one year high of $29.86 .

Also covering Dynavax Technologies Corporation's target, a total of 4 brokerages have issued a ratings update on the stock. The consensus target price is $43.75 with 1 equity analyst rating the company a strong buy, 3 firms rating the company a buy, zero brokers rating the stock a hold, zero firms rating the stock a underperform, and finally zero equity analysts rating the company a sell.

Brief Synopsis About Dynavax Technologies Corporation (NASDAQ:DVAX)

Dynavax Technologies Corporation (Dynavax) is a clinical-stage biopharmaceutical company. The Company uses toll-like receptor (TLR) biology to discover and develop vaccines and therapeutics. Its development programs are focused on vaccines and cancer immunotherapy. The Company's lead vaccine product candidate is HEPLISAV-B, an investigational adult hepatitis B vaccine, which combines its TLR9 agonist adjuvant and recombinant hepatitis B surface antigen (rHBsAg). Its lead cancer immunotherapy candidate is SD-101, a C Class CpG TLR9 agonist is selected for characteristics optimal for treatment of cancer, including high interferon induction. Its SD-101 clinical program is intended to assess the preliminary efficacy of SD-101 in a range of tumors and in combination with a range of treatments. Its advanced inflammatory disease candidate is AZD1419. Its pipeline of product candidates for cancer immunotherapy includes DV281 and CpG-Nanoparticles, which are in the preclinical stage.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *